Jim Simons Chinook Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$21.53 - $26.8 $1.4 Million - $1.74 Million	-65,100 Reduced 35.84%	116,562 $2.7 Million
Q4 2022 Feb 13, 2023	SELL	$18.63 - $27.35 $701,978 - $1.03 Million	-37,680 Reduced 17.18%	181,662 $4.76 Million
Q3 2022 Nov 14, 2022	SELL	$17.51 - $23.37 $938,886 - $1.25 Million	-53,620 Reduced 19.64%	219,342 $4.31 Million
Q2 2022 Aug 12, 2022	BUY	$12.59 - $18.8 $78,309 - $116,936	6,220 Added 2.33%	272,962 $4.77 Million
Q1 2022 May 13, 2022	SELL	$12.02 - $16.69 $1.22 Million - $1.7 Million	-101,900 Reduced 27.64%	266,742 $4.36 Million
Q4 2021 Feb 11, 2022	SELL	$10.69 - $16.83 $1.74 Million - $2.74 Million	-162,920 Reduced 30.65%	368,642 $6.01 Million
Q3 2021 Nov 12, 2021	SELL	$11.5 - $14.86 $1.31 Million - $1.69 Million	-113,580 Reduced 17.61%	531,562 $6.78 Million
Q2 2021 Aug 13, 2021	SELL	$13.6 - $18.98 $1.32 Million - $1.84 Million	-96,700 Reduced 13.04%	645,142 $9.11 Million
Q1 2021 May 13, 2021	SELL	$14.17 - $19.11 $1.34 Million - $1.8 Million	-94,244 Reduced 11.27%	741,842 $11.5 Million
Q4 2020 Feb 10, 2021	BUY	$11.9 - $20.91 $9.95 Million - $17.5 Million	836,086 New	836,086 $13.3 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.